Browse diseases

…Objectives Systemic Lupus Erythematosus (SLE) is characterised by pronounced clinical and immunological…

…Objectives Lupus nephritis (LN) is a major determinant of morbidity and mortality in syste…

…Objectives Lupus nephritis (LN) is a major complication in patients with systemic lupus er…

…3 years of follow-up. Biologic therapies are frequently used in systemic lupus erythematosus as well as in LN, yet information on the use of voclosporin in …

…Objectives Cognitive symptoms or ‘brain fog’ are common in systemic lupus erythematosus (SLE) and may reflect cognitive fatigue (CF) rather than measur…

…Objectives Lupus nephritis (LN) remains a major determinant of morbidity and mortality in …

… the 2019 EULAR/ACR criteria for SLE and presenting with severe SLE-ITP(<50,000/mm 3) with at least 6 months follow-up were included. T…

…5.2%), Black Caribbean (15.2%), Chinese (1.7%) or Other (3.3%). Lupus nephritis class was recorded. The mean number of months from diagnosis to…

…Objectives Cutaneous manifestations are common in systemic lupus erythematosus (SLE) and substantially contribute to disease burden. The Cutan…

…vel at 12 hours of 4-6 ug/L.Results Before TAC, the duration of lupus nephritis (LN) was 46 (in the range of 12-162) months. The drug therapy p…

…icoids (CG) use is a main driver of organ damage progression in Systemic Lupus Erythematosus (SLE). Updated EULAR SLE recommendations suggest avoiding the c…

…use. LC5 may provide a practical, structured method to identify SLE patients requiring therapeutic optimization, meriting validatio…